Clinical Blog
Published: February 15, 2023

Coming to AAAAI 2023: Propeller’s latest asthma research

The American Academy of Allergy, Asthma and Immunology (AAAAI) has accepted five abstracts examining the latest data from Propeller Health and ResMed.

Our findings on asthma care, which include analyzing the direct and indirect cost-savings associated with a digital intervention in uncontrolled asthma, will be presented at the AAAAI Annual Meeting on February 24-27. Read brief summaries of each abstract below or click the links to view them online.

Direct and indirect cost-savings associated with a digital intervention in uncontrolled asthma: A literature-based estimate

Summary: Uncontrolled asthma is associated with increased morbidity, healthcare utilization, cost, and lost productivity. Digital interventions have shown promise for patients with uncontrolled asthma, but there is limited evidence on cost-savings. Researchers conducted a literature-based analysis of the estimated one-year cost-savings for a clinically-integrated digital asthma program using Propeller’s digital therapeutic platform. Utilizing the findings from the literature-based analysis, it was estimated that a clinically-integrated digital program for uncontrolled asthma may result in annual total savings of approximately $2.25 million per thousand patients, including direct and indirect savings. Further evaluation of real-world costs is being conducted.

View this abstract online.

Short-acting beta-agonist (SABA) use by race and neighborhood socioeconomic status (nSES) among participants enrolled in a digital health program for asthma

Summary: Understanding the effectiveness of digital self-management programs among vulnerable populations living with asthma is an important step in building health equity. Using data on race and neighborhood socioeconomic status, we examined differences in SABA use among Propeller participants and found that there were similar improvements in SABA use, regardless of race or neighborhood socioeconomic status. These results suggest promise in supporting patients in their asthma management regardless of race or socioeconomic status. 

View this abstract online.

Identifying predictors of uncontrolled asthma symptoms despite high controller adherence

Summary: Certain patients may have an increased risk of uncontrolled asthma symptoms despite maintaining high controller adherence. Using inhaler sensor data, researchers assessed inhaler usage in children and adults with asthma over the course of 90 days. Despite being adherent to controller therapy, older patients (> 50 years) were almost twice as likely to have uncontrolled symptoms versus younger patients, and male patients were 50% more likely to have uncontrolled symptoms than females. These results suggest specific patients may require additional interventions to better maintain symptom management.

View this abstract online.

In addition to analyzing outcomes of Propeller patients, we also conducted research among a large, diverse population with asthma to understand trends in the burden of asthma broadly in the U.S. Below are two abstracts exploring adherence and costs among that population.

Adherence to controller therapy among a large, diverse sample of asthma patients in the United States

Summary: People living with persistent asthma often have suboptimal controller medication adherence rates, leading to uncontrolled symptoms and higher economic burden. Within the non-adherence range, reported rates vary dramatically. This is likely because of varying sample sizes, study designs, and data collection methods. To identify adherence trends, we used claims data from a large and diverse sample size of nearly 3 million people in the U.S. living with asthma. We found that while adherence rates ranged widely based on demographic and clinical characteristics, one sure trend is low adherence rates among children and adolescents. During follow-up, similar patterns persisted, although adherence was slightly higher. A better understanding of what drives adherence in varying patient groups is needed to improve asthma management.

View this abstract online.

Healthcare resource use and costs among a large, diverse sample of asthma patients in the United States

Summary: While the economic impact of asthma has been previously studied, burden estimates are outdated. This analysis examined real-world healthcare resource use (HCRU) and costs among a large and diverse sample of U.S. patients with mild, moderate, and severe asthma to determine the specific economic burden. On average, annual all-cause inpatient costs and annual all-cause ER costs were higher among patients with severe asthma than those with mild or moderate asthma. Given the high economic burden of severe asthma, research is needed to identify high-cost patients who may benefit from disease management interventions.

View this abstract online.

For any questions about Propeller’s peer-reviewed clinical research, please reach out to

You Might Also Like

Reducing Clinician Burnout: The Power of Using Digital Tools Effectively

It's no secret that health systems are feeling strained, with 47% of physicians experiencing symptoms of clinician burnout.1 An overwhelming amount of clinical data, jam-packed days with little time to connect with patients, and a lengthy list of responsibilities are leaving healthcare professionals feeling drained.

Clinician exhaustion can lead to reduced job satisfaction, increased turnover, and a decrease in the quality of care provided to patients. But burnout isn’t only harmful to teams — it can also cause financial strain on health systems. According to a study by the Annals of Internal Medicine, clinician exhaustion accumulates approximately $4.6 billion in costs due to turnover and reduced clinic hours.2

But when health systems use digital tools the right way, they can reduce the risk of clinician burnout and increase patient care coordination.

From 2010 to Today: Happy Birthday, Propeller!

Today marks an incredible milestone: Propeller Health's 13th birthday. What began as a quest to solve a public health problem has turned into a global precision digital health company driving meaningful, measurable change in the industry. 

Recognizing early on that creating value for all parties in health – health systems, clinicians, payers, and pharmaceutical companies – is essential in order to drive sustainable change, we’ve spent the past 13 years pioneering innovative solutions that always keep the patient at the center. Our story is one of hard work, dedication, collaboration, and above all, a mission to uplift every person living with a chronic disease so they can breathe easier, stay healthier, and live better lives. 

Propeller was founded on the heels of a then-mysterious string of asthma attacks in Barcelona in the 1980s. It took 8 years for experts to identify soybean dust – not yet recognized as an allergen – as the trigger. One CDC disease detective envisioned a better way to monitor public health: by using technology to track medication usage and symptoms. With this mission, Propeller was born. 

Pharma’s Biggest Takeaways From the 2023 J.P. Morgan Healthcare Conference

At J.P. Morgan’s 41st annual healthcare conference, there was no shortage of innovative discussions. We’ve rounded up some of the biggest themes from this year’s conference:

Connected drug delivery devices are gaining traction among top pharma companies

As medication non-adherence continues to plague the global life sciences industry – more than $600 billion in annual revenue is lost1 – many pharmaceutical companies are evaluating new approaches to improving patient engagement, including embedded sensors that capture data through drug delivery devices. One of the biggest selling points for organizations is that connected drug delivery devices can play a huge role in boosting adherence and compliance. Devices that can detect and capture data around patient-administered therapy, such as dose timing, volume, and technique, have become an increasingly popular choice among leading organizations. Patients are more likely to refill and take their medications on time, and correctly, if they can be prompted to do so and have a record of dosing history.